39 results on '"Sevcikova, Tereza"'
Search Results
2. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
3. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
4. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
5. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy.
6. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy
7. P-075 Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience
8. Eustigmatophyceae
9. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
10. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
11. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
12. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
13. Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis
14. Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia
15. Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma
16. Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets
17. P-020: Altered mRNA splicing identifies novel biomarkers and therapeutic targets in AL (Amyloid light-chain) Amyloidosis
18. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease
19. P-344 Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment
20. Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients
21. Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling
22. Intercellular Mitochondrial Transfer in the Tumor Microenvironment
23. P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes
24. Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib
25. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
26. Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets
27. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing
28. P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS.
29. Exome Sequencing of AL Amyloidosis Reveals Recurrently Mutated Genes
30. Novel Approach to Study Relationship Between Copy Number Variation and Gene Expression in Multiple Myeloma
31. Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression
32. Completion of cell division is associated with maximum telomerase activity in naturally synchronized cultures of the green alga Desmodesmus quadricauda
33. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview
34. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing.
35. Real‐World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.
36. Gene Expression Profile of Circulating Myeloma Cells Reveals CD44 and CD97 (ADGRE5) Overexpression
37. Whole Exome Sequencing of Plasma Cells Precancerosis MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes
38. Insight into the mechanism of CD34 + cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy.
39. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.